University of California San Diego, San Diego, CA, United States.
Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States.
Curr Drug Targets. 2018;19(7):740-747. doi: 10.2174/1389450118666170525114939.
Treatment strategies and treatment options have changed considerably over the past decade for Inflammatory Bowel Disease (IBD). Alongside this shift in therapeutic options has come an opportunity to personalize treatment decisions based on individual patient profiles and preferences. One of the most important aspects of therapy in IBD is treatment related risk, and an opportunity exists to personalize therapy through optimization of drug safety profiles in individual patients. In this review we discuss the potential risks of therapy in IBD, opportunities to mitigate those risks, and a personalized approach to consider when using these agents in clinical practice.
在过去的十年中,炎症性肠病(IBD)的治疗策略和治疗选择发生了很大的变化。随着治疗选择的转变,我们有机会根据患者的个体特征和偏好来个性化治疗决策。IBD 治疗中最重要的方面之一是与治疗相关的风险,并且有机会通过优化个体患者的药物安全性特征来实现个体化治疗。在这篇综述中,我们讨论了 IBD 治疗中的潜在风险、减轻这些风险的机会以及在临床实践中使用这些药物时需要考虑的个性化方法。